NewToInvesting7 wrote: It makes sense that covid revenues will be unpredictable going forward. I believe the majority of their covid testing revenues came from the US, and with so many people already vaccinated in the US, I don't think it's realistic to assume that there would continue to be a continuous upward trajectory for covid testing revenues.
I hope one of the reasons for any reduction in covid testing revenues, is because StageZero is starting/ramping up with cancer testing.
Regardless, I was happy to hear James mention twice, that the funds raised from the last 2 financings are sitting in the bank, and that they are using covid testing revenues for operational expenses, etc.
What I am curious about is the "100K commercial patients" that apparently used/were tested with Colon Sentry. Where are these revenues? With Oncore, and yet to be paid/distributed to StageZero? Or did StageZero perform tests free of charge, so as to collect and analyze the data, as it feeds into Aristotle?
Anyway, enough from me. I shall await the Q1 results, additional NRs, and the spot on B-TV.
Cheers!
molotov420 wrote: Thank god he didnt say 1+1=3 lol. Someone must have told him to cut that dumb shyt out.
One thing to note is he seemed to hint that Covid revs are unpredictable now...maybe we dont see such high amounts in one of the upcoming quarters.